Tilos Therapeutics
Lexington
About Tilos Therapeutics
Tilos Therapeutics is developing antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company's initial work is on antibodies specific for Latency Associated Peptide of TGF beta. Tilos was founded in 2016 and is based in Cambridge, Massachusetts.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $3.8M
- Funding stage: M&A
- Last round: Series Unknown (Sep 2017)
- Website: tilostherapeutics.com
- Phone: +1 508-233-3923
Industries & Categories
Biotechnology, Oncology, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/tilos-therapeutics-23639 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.